AstraZeneca stock after-hours reference at EUR 140.40
Published on 10/02/2026 at 23:18 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
AstraZeneca stock’s after-hours reference was EUR 140.40 at Lang & Schwarz, based on the prior close of October 1, 2026. The next price is shown from the start of trading by the continuously updated real-time quote of AstraZeneca stock.
Clinical collaboration targets breast cancer trial
On October 2, 2026, AstraZeneca and Daiichi Sankyo announced a clinical collaboration with Summit Therapeutics to evaluate Datroway in combination with ivonescimab across multiple tumor types. The companies intend to begin with a Phase III trial in first-line triple-negative breast cancer. Each company will contribute its respective medicine, while AstraZeneca or Daiichi Sankyo will sponsor the planned combination trials. AstraZeneca said the companies will each contribute to trial costs and retain development and commercial rights to their respective medicines.
Shares admitted under employee schemes
AstraZeneca PLC also reported on October 1, 2026, that 9,828 ordinary shares had been issued and admitted to trading under its employee share schemes. The total number of securities in issue following the admission was 1,551,053,289, according to the company’s RNS notification. RNS identified the listed issuer as AstraZeneca PLC and the regulated market as the London Stock Exchange Main Market.
